Durable Weight Loss Follows Just a Few Injections of Novel Drug

A once-monthly injectable weight management medication safely induced long-term weight loss in a phase I human experiment.

At the maximum dose tested, people with overweight or obesity lost 14.5% of their body weight by day 85. 

Murielle Véniant, PhD, of Amgen Research in Thousand Oaks, California, and colleagues reported in Nature Metabolism, which opens in a new tab or window.

At 150 days after the last dosage, this high-dose group maintained an 11.2% weight decrease from baseline.

Maridebart cafraglutide, also known as MariTide and earlier as AMG 133, is a first-in-class experimental drug that inhibits the stomach inhibitory polypeptide receptor (GIPR) while activating the glucagon-like peptide 1 (GLP-1) receptor.

"The combination of an anti-GIPR monoclonal antibody ... and a GLP-1RA has been shown to mediate more pronounced weight loss than either agent alone in preclinical obesity models," the authors of the study noted.

They noted that because the chemical has a longer half-life than other similar medicines on the market, dosing intervals can be increased while still achieving the majority of the weight loss.

Current GLP-1 receptor agonists on the market for weight reduction, such as semaglutide (Wegovy)opens in a new tab or window and tirzepatide (Zepbound), are injected once weekly and have been proven to cause weight regainopens in a new tab or window after withdrawal.

Love Horoscope For February 1, 2024 Brings Change

For More WebStories